Key result
High-risk patients worldwide remain largely undertreated for dyslipidemia despite the introduction of more aggressive lipid-lowering guidelines.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Highlights the ongoing gap between aggressive lipid-lowering guidelines and actual clinical practice in high-risk patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Peter P. Tóth (2025) studied this question. High-risk patients worldwide remain largely undertreated for dyslipidemia despite the introduction of more aggressive lipid-lowering guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: